
    
      This is a Phase 2a proof of concept study evaluating the safety/efficacy of retigabine vs.
      placebo in patients with post-herpetic neuralgia. After screening, patients will enter a
      maximum 6 week titration period followed by a 4 week maintenance period and a 3 week taper
      phase.
    
  